<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579799</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-NR. 2012-0005</org_study_id>
    <nct_id>NCT01579799</nct_id>
  </id_info>
  <brief_title>The Effect of L-lysine on Human Gastrointestinal Secretion: A Dose-finding Study Applying Magnetic Resonance Imaging (MRI)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      This is a pilot dose-finding study, which is performed with a randomized, double-blind,
      3-armed, unbalanced, cross-over study design. Three of four different doses of L-lysine
      Monohydrate (A = 0.5 g, B = 1.2 g, C = 3.0 g and D = 7.5 g) will be applied in a randomized
      sequence on three different study days in six healthy volunteers. Each study day involves the
      repeated measurement of gastric content volume, gastric secretion volume and intestinal fluid
      volume using MRI before and after intragastric infusion of L-lysine Monohydrate test meals.
      Additionally, symptoms for hunger, fullness, nausea, bloating, abdominal cramps and urge to
      defecate will be recorded using a scale from 0-10. In parallel, samples of gastric juice to
      measure intragastric pH and pepsin concentration, samples of venous blood to assess blood pH
      and haematocrit as well as L-lysine, Serotonin, chloride bicarbonate and albumin plasma
      concentration and samples of arterialized blood from ear lobe to measure glucose blood
      concentration will be collected
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric half-emptying time</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 0.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-lysine</intervention_name>
    <description>Dose finding study for L-lysine</description>
    <arm_group_label>Dose 0.5</arm_group_label>
    <arm_group_label>Dose 7.5</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_label>Dose 1.2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: &gt; 18, &lt; 50 years Healthy BMI &gt; 19, &lt;24

        Exclusion criteria: Age under 18 or above 50

          -  Pathologic underweight or overweight (BMI &lt;19 or &gt;24 (kg/m2))

          -  Previous gastrointestinal, cardio-respiratory (incl. arterial hypertension),
             hematologic (anaemia), renal, hepatic, atopic, alimentary disease, psychiatric
             disease, epilepsy, panic attacks, diabetes drug or alcohol abuse, lysinuria,
             galactosaemia

          -  Subjects unable to stop medication that alters gut function for 1 week prior to the
             study, including anticholinergics, calcium canal inhibitors, beta blocker,
             prokinetics, proton-pump inhibitors, DDV-IV-Inhibitors, Incretin-mimetics,
             non-steroidal anti-inflammatory drugs, Macrolidantibiotica

          -  Subjects unable to stop medication within 48 prior the study begins that alters
             serotonin blood profiles , including paracetamol, cumarine, mephenesin, phenobarbital,
             acetanilide, ephedrine, amphetamine, phentolamin, phenacetin, methocarbamol,
             acetylsalicylic acid, levodopa, promethazine, isoniazid, methenamine, streptozocin,
             chlorpromazine

          -  Positive helicobacter pylori test

          -  Previous history of gastrointestinal disease or surgery (excludes appendectomy, hernia
             repair and anorectal disorders)

          -  Presence of metallic implants, devices or metallic foreign bodies

          -  Pregnancy and lactation (female patients of child bearing age will receive a pregnancy
             test prior to study)

          -  Involvement in any other clinical trial during the course of this trial, nor within a
             period of 14 days prior to its beginning or 14 days after its completion

          -  Mental capacity (DSM IV, inter alia Claustrophobia), which limits the capability to
             fulfill the demands of the study

          -  Known allergy or intolerance against capsaicin, locus bean gum, L-lysine, DOTAREMÂ®,
             Fructose, Gluten, Galactose Known allergic reaction after prior injection of lidocaine
             (e.g. at the dentist )

          -  Known allergic reaction toward methylparaben (E218)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Schwizer, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Gastroenterology &amp; Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Gastroenterology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

